Vaginosis, Bacterial Clinical Trial
Official title:
A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Metronidazole Vaginal Gel 1.3% in Adolescent Female Subjects With Bacterial Vaginosis
Verified date | August 2023 |
Source | Insud Pharma |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Multicenter, open-label study to evaluate safety and tolerability of Metronidazole Vaginal Gel in females 12 to <18 years for the treatment of bacterial vaginosis.
Status | Completed |
Enrollment | 60 |
Est. completion date | October 5, 2016 |
Est. primary completion date | October 5, 2016 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 12 Years to 17 Years |
Eligibility | Inclusion Criteria: - Provide written assent and parent/legal guardian informed consent and authorization to disclose protected health information. - Post-menarcheal, adolescent female, 12 to <18 years of age at time of Screening/Baseline Visit (Day 1). - In good general health at Screening visit with no known medical conditions that, in the Investigator's opinion, may interfere with study participation. - Has negative urine pregnancy test result prior to study treatment initiation. - Has clinical diagnosis of bacterial vaginosis. - Agree to abstain from sexual intravaginal intercourse for study duration. - Willing to avoid alcohol ingestion for 24 hours after administration of test article. - Agree to refrain from use of intravaginal products for duration of study (e.g. lubricated condoms, tampons, diaphragms, spermicides, feminine deodorant sprays, douches). Intravaginal Uterine Device (IUD) use is acceptable as long as it has been in place for 30 days prior to study enrollment. - Willing and able to participate in study, make required visits to the study center, and comply with all study requirements including concomitant medication and other treatment restrictions. Exclusion Criteria: - Pregnant, lactating, or planning to become pregnant during study period. - Currently menstruating or anticipate onset of menses during first 9 days of the study. - Experience a clinically important medical event with 90 days of Screening/Baseline Visit (Day 1). - Evidence of other infectious causes of vulvovaginal infection or condition that in the Investigator's opinion would confound the interpretation of the study results. - Severe symptoms of dysuria and/or pruritus, burning or irritation in vulvovaginal area. - Received systemic or intravaginal antifungal, antibacterial or antiparasitic drugs within 14 days of Screening/Baseline visit (Day 1). Antiviral therapies (non-intravaginal) are acceptable. - Has taken disulfiram or systemic corticosteroids (oral or injected) within 14 days of Screening/Baseline Visit (Day 1). - Had sexual intravaginal intercourse within 24 hours of Screening/Baseline (Day 1). - Demonstrated previous hypersensitivity to metronidazole, either orally or topically administered, or any form of parabens or benzyl alcohol. - Known primary or secondary immunodeficiency condition/syndrome. - Being treated or planning to be treated during the study period for cervical intraepithelial neoplasia (CIN) or cervical carcinoma. - Using anticoagulation therapy with Coumadin (warfarin). - Previously treated with test article under this protocol. - Participate in an experimental drug/device trial within the last 30 days before Screening/Baseline Visit (Day 1). - Is judged by the Investigator to be unsuitable for any reason. |
Country | Name | City | State |
---|---|---|---|
United States | Allergan Research Site #315 | Bardstown | Kentucky |
United States | Allergan Research Site #319 | Columbus | Ohio |
United States | Allergan Research Site #322 | Dayton | Ohio |
United States | Allergan Research Site #316 | Irving | Texas |
United States | Allergan Research Site #318 | Long Beach | California |
United States | Allergan Research Site #321 | Memphis | Tennessee |
United States | Allergan Research Site #314 | New Orleans | Louisiana |
United States | Allergan Research Site #324 | Paramount | California |
Lead Sponsor | Collaborator |
---|---|
Insud Pharma | Allergan Sales, LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of subjects with treatment-emergent adverse events (AEs), serious AEs, treatment-related AEs and AEs leading to study discontinuation after Metronidazole Vaginal Gel is administered in post-menarcheal, adolescent females with bacterial vaginosis. | No serious AEs reported during the completed study | up to 10 days | |
Primary | A multicenter open label to evaluate safety and tolerability of metronidazole vaginal gel 1.3% for adolescents female subject with bacterial and vaginosis | Metronidazole Vaginal Gel 1.3% is safe, well tolerated, and efficacious in treating vaginal discharge and odor in adolescent females aged 12 to < 18 years with bacterial vaginosis. The safety and efficacy profiles in this study were consistent with the known safety and efficacy profiles for the adult population and no new safety concerns were identified. | up tp 10 days | |
Secondary | Number of subjects reporting presence of daily vaginal discharge and/or odor following single dose administration of Metronidazole Vaginal Gel 1.3%assessment of the presence of vaginal discharge and odor following single dose administration. | no order or smelling observed | up to 10 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT02558179 -
Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method
|
N/A | |
Completed |
NCT02314429 -
Trial Evaluating the Safety of a Lactate Releasing Vaginal Ring for the Prophylaxis of Bacterial Vaginosis
|
Phase 1 | |
Completed |
NCT02272231 -
Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women
|
||
Completed |
NCT02139839 -
Exploratory Study to Evaluate the Effects of the Probiotics L. Rhamnosus GR-1 and L. Reuteri RC-14
|
Phase 0 | |
Recruiting |
NCT01448291 -
Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers
|
Phase 4 | |
Recruiting |
NCT03500107 -
Use of Blue Light Emitting Diode in the Treatment of Women With Bacterial Vaginosis: a Clinical Trial
|
N/A | |
Completed |
NCT00153517 -
Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy
|
Phase 2 | |
Completed |
NCT04989543 -
Study of the Composition and Bacterial Diversity of the Vaginal Microbiota in Healthy Versus Pathological Conditions (Bacterial Vaginosis) Using a Targeted Metagenomic Approach (RNA 16s)
|
N/A | |
Completed |
NCT02641717 -
Validity of Patient-Collected Wet Mounts
|
N/A | |
Terminated |
NCT03943823 -
Postmenopausal Pessary Users: Estrogen Versus Trimosan
|
Phase 4 | |
Completed |
NCT03134924 -
Vaginal Practices in Human Immunodeficiency Virus (HIV) Positive Women in Zambia, a Bio-Behavioral Intervention "WASH-2"
|
N/A | |
Completed |
NCT01293643 -
A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077)
|
Phase 3 | |
Terminated |
NCT01153958 -
Colposeptine for the Treatment of Bacterial Vaginosis
|
Phase 4 | |
Completed |
NCT00484653 -
Identification and Impact of Vaginal Flora Anomalies Among Pregnant Woman
|
N/A | |
Completed |
NCT05649735 -
EFFICACY AND SAFETY OF OVA AND LAVAGE MEDICAL DEVICES IN THE TREATMENT OF NON-SPECIFIC VULVOVAGINITIS
|
N/A | |
Completed |
NCT02860845 -
Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections
|
Phase 4 | |
Not yet recruiting |
NCT00491270 -
Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery
|
Phase 3 | |
Completed |
NCT01055106 -
Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis
|
Phase 2 | |
Terminated |
NCT01322971 -
Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population
|
N/A | |
Completed |
NCT04171947 -
Vaginal Ovule With Flavonoid Tea Extract for the Correction of Imbalance in the Vaginal Environment
|
N/A |